A definitive therapy for oral squamous cell carcinoma (OSCC) in dogs remains elusive; directing efforts toward targeting EGFR and COX-2 in veterinary clinical oncology holds promise in unveiling fresh perspectives on cancer biology and the efficacy of advanced targeted therapies. This evidence concerns the gene PTGS2 and cancer.